FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 322:1764-1768 June 21, 1990 Number 25 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Propranolol and the sodium-channel-blocking antiarrhythmic agent propafenone share structural features. Although propafenone's beta-blocking actions are readily demonstrable in vitro, clinically significant beta-blockade occurs inconsistently in vivo. In this study, we tested the hypothesis that genetically determined variations in the biotransformation of propafenone to its 5-hydroxy metabolite account for variations in the drug's beta-blocking action. We assessed beta-blockade by measuring the reduction in tachycardia produced by boluses of isoproterenol and treadmill exercise in 14 normal subjects during treatment with placebo and with 150, 225, and 300 mg of propafenone every eight hours for five days each. Nine subjects (with the extensive-metabolizer phenotype) metabolized most of the propafenone to 5-hydroxy propafenone, and five (with the poor-metabolizer phenotype) did not produce this metabolite. At the lower dosages, beta-blockade was present in both groups but was significantly greater in the subjects with poor metabolism, in whom deficient 5-hydroxylation was associated with higher plasma propafenone levels. At the highest dose, a similar degree of beta-blockade was observed in the two groups. Propafenone also had a higher affinity for beta 2 receptors in vitro than either of its major metabolites. We conclude that the degree of beta-blockade during propafenone therapy reflects genetically determined variations in the metabolism of the parent drug, which is necessary for beta-blockade, and that this action of propafenone is considerably enhanced in patients with deficient 5-hydroxylation of propafenone.

Source Information

Department of Medicine, Vanderbilt University, Nashville, TN 37232.

This article has been cited by other articles:

• Gardiner, S. J., Begg, E. J. (2006). Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice. Pharmacol. Rev. 58: 521-590 [Abstract] [Full Text]  
• Roden, D. M. (2005). Proarrhythmia as a pharmacogenomic entity: A critical review and formulation of a unifying hypothesis. Cardiovasc Res 67: 419-425 [Abstract] [Full Text]  
• Evans, W E (2003). Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut 52: ii10-18 [Abstract] [Full Text]  
• Arias, C., Gonzalez, T., Moreno, I., Caballero, R., Delpon, E., Tamargo, J., Valenzuela, C. (2003). Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels. Cardiovasc Res 57: 660-669 [Abstract] [Full Text]  
• Roden, D. M (2000). ELECTROPHYSIOLOGY: Antiarrhythmic drugs: from mechanisms to clinical practice. Heart 84: 339-346 [Full Text]  
• Evans, W. E., Relling, M. V. (1999). Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 286: 487-491 [Abstract] [Full Text]  
• Valderrabano, M., Singh, B. N. (1999). Review : Electrophysiologic and Antiarrhythmic Effects of Propafenone: Focus on Atrial Fibrillation. J CARDIOVASC PHARMACOL THER 4: 183-198  
• Lam, Y.W. F., Marshall, M. V. (1992). Genetically Determined Polymorphisms in Drug Metabolism. Journal of Pharmacy Practice 5: 317-336 [Abstract]  
• Straka, R. J., Marshall, P. S. (1992). The Clinical Significance of the Pharmacogenetics of Cardiovascular Medications. Journal of Pharmacy Practice 5: 337-361 [Abstract]